This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Dr. Gonzalez and his team developed a model to determine if it was cost-effective to treat U.S. hepatitis C with all oral direct acting antivirals for HCC patients on the waiting list for liver transplant. The goal was to determine if was more cost-effective to treat pre-transplant or post-transplant. Data related to transition to progression of HCC and progression of disease and the efficacy of antiviral therapy were used for the analysis.
The study found that it was cost-effective to treat pre-transplant. Treating before transplant also decreased liver-related mortality and increased sustained virologic response, says Gonzalez. Pre-treatment did not have any impact at time of the liver transplant waitlist.